Skip to main content
Carryn (Ensrude) Anderson, MD, Radiation Oncology, Iowa City, IA

CarrynM(Ensrude)AndersonMD

Radiation Oncology • Iowa City, IA

Assistant Professor, Radiation Oncology, University of Iowa College of Medicine

Join to view full profile

Dr. Anderson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Anderson's full profile

Already have an account?

  • Office

    200 Hawkins Dr
    01614 Pfpw
    Iowa City, IA 52242
    Phone+1 319-353-8836
    Fax+1 319-356-1530

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Radiation Oncology, 2003 - 2008
  • University of Texas Medical Branch School of Medicine
    University of Texas Medical Branch School of MedicineClass of 2003

Certifications & Licensure

  • IA State Medical License
    IA State Medical License 2008 - 2025
  • OH State Medical License
    OH State Medical License 2003 - 2025
  • American Board of Radiology Radiation Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset o... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Avasopasem Promising for Severe Oral Mucositis During IMRT for Locally Advanced Head and Neck Cancers
    Avasopasem Promising for Severe Oral Mucositis During IMRT for Locally Advanced Head and Neck CancersJune 4th, 2022
  • Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis
    Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral MucositisMarch 1st, 2020
  • Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting
    Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual MeetingJune 29th, 2018
  • Join now to see all

Dr. Carryn Anderson, Dr. Carryn Anderson, MD, Dr. C Anderson, Dr. Carryn M Anderson